T1	Participants 339 394	patients with intermediate-stage Hodgkin's disease (HD)
T2	Participants 418 518	HD patients in stage I to IIIA with a large mediastinal mass, E stage, or massive spleen involvement
T3	Participants 988 1085	111 patients who fulfilled the same inclusion criteria in the subsequent trial HD5 (1988 to 1993)
T4	Participants 802 844	146 patients who responded to chemotherapy
